Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following factors has the maximum effect on the filtration of a drug by the glomerulus?

Plasma protein binding. **Explanation:** **Glomerular filtration** is a passive process where drugs are filtered through the capillary pores of the glomerulus [1]. The primary determinant of this process is the **molecular size** and the **free (unbound) fraction** of the drug [2]. 1. **Why Plasma Protein Binding is Correct:** Drugs in the plasma exist in two forms: bound to proteins (like albumin) and free. The glomerular filtration barrier acts as a sieve that prevents large molecules like plasma proteins from passing through [3]. Consequently, any drug molecule bound to a protein becomes too large to be filtered. Therefore, the **rate of filtration is directly proportional to the free fraction** of the drug [2]. High protein binding significantly limits glomerular filtration. 2. **Why Other Options are Incorrect:** * **Lipid Solubility & Degree of Ionization:** Unlike tubular reabsorption (which is highly dependent on lipid solubility and pH-dependent ionization), glomerular filtration is a bulk flow process through large pores [1]. It does not require the drug to cross lipid membranes; thus, lipid solubility and ionization have **no significant effect** on filtration. * **Rate of Tubular Secretion:** This is a separate process occurring in the renal tubules via active transporters (e.g., OAT, OCT). While it contributes to the total renal clearance, it does not influence the filtration occurring at the glomerulus [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Glomerular Filtration Rate (GFR):** Only the **unbound** drug is filtered [2]. * **Tubular Secretion:** Can clear both **bound and unbound** drugs (e.g., Penicillin is highly protein-bound but rapidly cleared via secretion) [2]. * **Tubular Reabsorption:** Highly dependent on **Lipid solubility** and **pH** (Ion trapping). * **Formula:** Renal Clearance = (Filtration + Secretion) – Reabsorption.

Q: Which of the following drugs is metabolized through glycin(e) conjugation?

Nicotinic acid. **Explanation:** **Correct Option: D (Nicotinic acid)** Metabolism occurs via two main phases: Phase I (Functionalization) and Phase II (Conjugation). **Glycine conjugation** is a specific Phase II pathway used for compounds containing a carboxylic acid group. **Nicotinic acid (Niacin)** and **Salicylates** (Aspirin) are the classic examples of drugs metabolized through this pathway. In this process, the drug is activated to a Coenzyme A thioester, which then reacts with glycine to form a water-soluble conjugate (e.g., nicotinuric acid) for renal excretion. **Analysis of Incorrect Options:** * **A. Benzodiazepines:** These drugs primarily undergo Phase I oxidation (via CYP3A4/2C19) followed by **Glucuronidation** (Phase II). Note: "LOT" drugs (Lorazepam, Oxazepam, Temazepam) undergo direct glucuronidation, bypassing Phase I. * **B. Atazanavir:** This protease inhibitor is extensively metabolized in the liver primarily by the **CYP3A4** isoenzyme (Phase I). * **C. Ifosfamide:** This alkylating agent is a prodrug that requires activation by **CYP3A4 and CYP2B6** (Phase I) to form its active metabolite, ifosfamide mustard. **High-Yield Clinical Pearls for NEET-PG:** * **Phase II Conjugation Mnemonic:** Remember **"S-G-A-G"** (Sulfation, Glucuronidation, Acetylation, Glycine conjugation). * **Glucuronidation** is the most common Phase II reaction. * **Acetylation** shows genetic polymorphism (Fast vs. Slow acetylators); drugs involved include **S**ulfonamides, **H**ydralazine, **I**soniazid, and **P**rocainamide (**SHIP**). * **Gray Baby Syndrome** occurs in neonates due to a deficiency of **UDP-glucuronyltransferase**, preventing the conjugation of Chloramphenicol.

Q: Which of the following terms best describes a drug that blocks the action of adrenaline at its receptors by occupying those receptors without activating them?

Pharmacologic antagonist. ### Explanation **1. Why Option A is Correct:** A **pharmacologic antagonist** is a drug that binds to the same receptor as an agonist (in this case, adrenaline) but does not activate it. By occupying the receptor site, it prevents the agonist from binding and exerting its effect. This is the classic definition of receptor-level blockade. Since it competes for the same binding site, it is also often referred to as a competitive antagonist. **2. Why the Other Options are Incorrect:** * **B. Non-competitive antagonist:** These drugs do not simply "occupy" the receptor site to block the agonist; they either bind irreversibly to the active site or bind to an **allosteric site**, changing the receptor's shape so the agonist cannot trigger a response. Unlike pharmacologic antagonists, their effect cannot be overcome by increasing agonist concentration. * **C. Physiologic antagonist:** This refers to two drugs acting on **different receptors** to produce opposite effects in the same system. *Example:* Histamine (bronchoconstriction via H1) vs. Adrenaline (bronchodilation via β2). * **D. Chemical antagonist:** This involves a direct chemical reaction between two substances in solution, neutralizing the drug before it reaches a receptor. *Example:* Protamine sulfate neutralizing Heparin. **3. NEET-PG High-Yield Pearls:** * **Competitive Antagonism:** Shifts the Dose-Response Curve (DRC) to the **right** (increases $EC_{50}$), but the **maximal efficacy ($E_{max}$) remains unchanged**. * **Non-competitive Antagonism:** Flattens the DRC, **decreasing the $E_{max}$**, while the $EC_{50}$ usually remains the same. * **Inverse Agonist:** Binds to the same receptor as an agonist but produces an effect **opposite** to that of the agonist (e.g., Beta-carbolines at GABA receptors).

Q: Which of the following terms best describes the antagonism of the bronchoconstrictor effect of leukotrienes (mediated at leukotriene receptors) by terbutaline (acting at adrenoceptors) in a patient with asthma?

Physiologic antagonist. **Explanation:** The correct answer is **Physiologic antagonist (Option C)**. **1. Why it is correct:** Physiologic (or functional) antagonism occurs when two drugs act on **different receptors** to produce **opposing physiological effects** on the same biological system [1]. In this scenario: * **Leukotrienes** act on leukotriene receptors to cause bronchoconstriction [4]. * **Terbutaline** acts on $\beta_2$-adrenoceptors to cause bronchodilation [1], [3]. Because they achieve opposite results (constriction vs. dilation) through independent pathways, they are physiologic antagonists. **2. Why the other options are wrong:** * **Pharmacologic antagonist (A):** This involves a drug binding to the **same receptor** as the agonist to block its action (e.g., Montelukast blocking leukotriene receptors). * **Partial agonist (B):** This is a drug that binds to the same receptor as a full agonist but produces a sub-maximal response (e.g., Pindolol at $\beta$-receptors) [2]. * **Chemical antagonist (D):** This occurs when two substances react **chemically** with each other in solution, neutralizing the drug before it reaches a receptor (e.g., Protamine neutralizing Heparin or Chelating agents). **Clinical Pearls for NEET-PG:** * **Classic Example:** Histamine (H1 receptors) vs. Adrenaline ($\beta_2$ receptors) in anaphylaxis is the most frequently tested example of physiologic antagonism. * **Glucagon vs. Insulin:** These are physiologic antagonists regarding blood glucose levels. * **Key Distinction:** Unlike competitive antagonism, physiologic antagonism cannot be fully overcome by simply increasing the dose of the agonist, as the mechanisms are independent.

Q: Which of the following does NOT induce microsomal enzymes?

Cimetidine. **Explanation:** The core concept tested here is the distinction between **Enzyme Inducers** and **Enzyme Inhibitors**. Microsomal enzymes (primarily the Cytochrome P450 system in the liver) are responsible for the metabolism of many drugs. **1. Why Cimetidine is the correct answer:** Cimetidine is a potent **Enzyme Inhibitor**. It binds to the heme iron of the CYP450 system, reducing the metabolic activity of the liver. This leads to decreased clearance and increased plasma concentrations of co-administered drugs (like Warfarin or Theophylline), potentially causing toxicity. **2. Why the other options are incorrect:** * **Phenobarbitone:** A classic, potent inducer of CYP450 enzymes. It increases the synthesis of microsomal enzymes, accelerating the metabolism of itself and other drugs. * **Rifampicin:** One of the most powerful known enzyme inducers. It significantly reduces the half-life of drugs like oral contraceptives, often leading to therapeutic failure. * **Griseofulvin:** An antifungal agent known to induce hepatic microsomal enzymes, particularly affecting the metabolism of Warfarin. **High-Yield Clinical Pearls for NEET-PG:** To remember these for the exam, use these popular mnemonics: * **Enzyme Inducers (GPRS Cell Phone):** **G**riseofulvin, **P**henytoin/Phenobarbitone, **R**ifampicin, **S**moking, **C**arbamazepine. * **Enzyme Inhibitors (VITAMIN K):** **V**alproate, **I**soniazid, **T**erfenadine, **A**miodarone, **M**ethylphenidate, **I**traconazole, **N**ight (Grapefruit) juice, **K**etoconazole (**C**imetidine and **E**rythromycin are also critical inhibitors). **Note:** Cimetidine also has anti-androgenic side effects (gynecomastia), making it a frequent topic in NEET-PG pharmacology questions.

Q: When atrial fibrillation persists despite digoxin therapy, an inadequate digoxin dose is suspected. Plasma levels of digoxin for confirmation are typically drawn after a certain interval following the last dose. Considering pharmacokinetic principles, which factor is most crucial for determining this appropriate sampling time?

Rate of distribution. **Explanation:** The correct answer is **Rate of distribution (Option B)**. This is a classic pharmacokinetic concept essential for drugs that follow a **two-compartment model**, such as digoxin. Digoxin has a prolonged distribution phase (6–8 hours). After administration, the drug initially remains in the central compartment (blood) before moving into the peripheral compartment (tissues like the myocardium). Since the pharmacological effect of digoxin occurs at the tissue level, plasma levels drawn during the distribution phase will be falsely elevated and will not correlate with the drug’s clinical effect or toxicity. Therefore, sampling must be delayed until the **distribution equilibrium** is reached to ensure the plasma concentration reflects the tissue concentration. **Why other options are incorrect:** * **Rate of absorption (A):** While absorption determines how fast a drug enters the blood, it does not dictate the equilibrium between blood and the target organ (heart). * **Rate of clearance (C) and Elimination (D):** These factors determine the **half-life** and the time required to reach **steady-state** (usually 4–5 half-lives). While they influence the maintenance dose, they do not determine the specific timing of a post-dose sample (trough level) as critically as the distribution phase does for digoxin. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** For Digoxin, blood should be drawn at least **6 to 8 hours** after the last dose. * **Volume of Distribution ($V_d$):** Digoxin has a very high $V_d$ (~7 L/kg) because it binds extensively to skeletal muscle. * **Therapeutic Window:** Narrow (0.5–2.0 ng/mL). * **Toxicity Predisposition:** Hypokalemia, hypomagnesemia, and hypercalcemia increase the risk of digoxin toxicity.

Q: Which of the following is NOT a type of oxidative drug metabolism?

Glucuronidation. ### Explanation Drug metabolism (biotransformation) is divided into two main phases: **Phase I (Non-synthetic)** and **Phase II (Synthetic)**. **Why Glucuronidation is the Correct Answer:** Glucuronidation is a **Phase II reaction**. It involves the conjugation of a drug with glucuronic acid (derived from glucose) via the enzyme **UDP-glucuronosyltransferase (UGT)**. Unlike Phase I reactions, which introduce or expose functional groups, Phase II reactions attach large, polar endogenous molecules to the drug to make it water-soluble for excretion. **Why the other options are incorrect:** Options A, B, and C are all subtypes of **Phase I Oxidative reactions**, primarily mediated by the **Cytochrome P450 (CYP450)** enzyme system: * **Deamination (A):** Removal of an amino group (e.g., metabolism of Amphetamine). * **N-oxidation (B):** Addition of oxygen to a nitrogen atom (e.g., metabolism of Trimethylamine). * **N-dealkylation (C):** Removal of an alkyl group attached to a nitrogen atom (e.g., Morphine to Normorphine). **High-Yield Clinical Pearls for NEET-PG:** * **Phase I Reactions:** Oxidation (most common), Reduction, and Hydrolysis. * **Phase II Reactions:** Glucuronidation (most common Phase II), Acetylation, Methylation, and Sulfate conjugation. * **Microsomal vs. Non-microsomal:** Glucuronidation is the **only** Phase II reaction carried out by microsomal enzymes (located in the smooth ER). All other Phase II reactions are non-microsomal (cytosolic). * **Gray Baby Syndrome:** Occurs in neonates due to a deficiency of the UGT enzyme, leading to the inability to conjugate Chloramphenicol.

Q: A drug has 40% absorption and a hepatic extraction ratio of 0.6. What is the bioavailability of the drug?

16%. **Explanation** The bioavailability ($F$) of an orally administered drug is determined by the fraction of the dose absorbed from the gastrointestinal tract and the fraction that escapes first-pass hepatic metabolism. **1. Why the Correct Answer (16%) is Right:** Bioavailability is calculated using the formula: $F = f \times (1 - ER)$ Where: * **$f$ (Absorption):** 40% or 0.4 * **$ER$ (Extraction Ratio):** 0.6 * **$(1 - ER)$:** This represents the **Hepatic Bioavailability** (the fraction of the drug that survives the liver). Calculation: $F = 0.4 \times (1 - 0.6)$ $F = 0.4 \times 0.4 = 0.16 \text{ or } 16%$ Thus, only 16% of the administered dose reaches the systemic circulation. **2. Why the Incorrect Options are Wrong:** * **B (20%):** This is a distractor often reached by miscalculating the hepatic survival or averaging the numbers. * **C (24%):** This is the result of multiplying 40% by 0.6 ($0.4 \times 0.6 = 0.24$). This represents the amount of drug **metabolized** by the liver, not the amount that reaches the circulation. * **D (28%):** This does not correlate with the mathematical relationship between absorption and extraction. **3. NEET-PG Clinical Pearls:** * **First-Pass Effect:** Drugs with a high Extraction Ratio (e.g., Nitroglycerin, Propranolol, Lidocaine) have low oral bioavailability and are often given via sublingual or IV routes. * **Bioavailability ($F$) of IV drugs:** Always 100% ($F=1$). * **Area Under the Curve (AUC):** Bioavailability is also calculated by comparing the AUC of oral administration to the AUC of IV administration ($F = \text{AUC}_{\text{oral}} / \text{AUC}_{\text{IV}}$). * **Liver Disease:** In cirrhosis, the extraction ratio decreases, which can significantly increase the bioavailability (and toxicity) of drugs with high first-pass metabolism.

Question 1

Which of the following factors has the maximum effect on the filtration of a drug by the glomerulus?

Accepted Answer

Plasma protein binding

Answer

Lipid solubility

Answer

Degree of ionization

Answer

Rate of tubular secretion

Question 2

Which of the following drugs is metabolized through glycin(e) conjugation?

Accepted Answer

Nicotinic acid

Answer

Benzodiazepines

Answer

Atzanavir

Answer

Ifosfamide

Question 3

Which of the following terms best describes a drug that blocks the action of adrenaline at its receptors by occupying those receptors without activating them?

Accepted Answer

Pharmacologic antagonist

Answer

Non-competitive antagonist

Answer

Physiologic antagonist

Answer

Chemical antagonist

Question 4

Which of the following terms best describes the antagonism of the bronchoconstrictor effect of leukotrienes (mediated at leukotriene receptors) by terbutaline (acting at adrenoceptors) in a patient with asthma?

Accepted Answer

Physiologic antagonist

Answer

Pharmacologic antagonist

Answer

Partial agonist

Answer

Chemical antagonist

Question 5

Which of the following does NOT induce microsomal enzymes?

Accepted Answer

Cimetidine

Answer

Griseofulvin

Answer

Rifampicin

Answer

Phenobarbitone

Question 6

When atrial fibrillation persists despite digoxin therapy, an inadequate digoxin dose is suspected. Plasma levels of digoxin for confirmation are typically drawn after a certain interval following the last dose. Considering pharmacokinetic principles, which factor is most crucial for determining this appropriate sampling time?

Accepted Answer

Rate of distribution

Answer

Rate of absorption

Answer

Rate of clearance

Answer

Rate of elimination

Question 7

At 12 hours after intravenous administration of a bolus dose, the plasma level of a drug is 3 mg/L. If the volume of distribution (Vd) is 10 L and the elimination half-life is 6 hours, what was the dose administered?

Accepted Answer

120 mg

Answer

180 mg

Answer

240 mg

Answer

480 mg

Question 8

Which of the following is NOT a type of oxidative drug metabolism?

Accepted Answer

Glucuronidation

Answer

Deamination

Answer

N-oxidation

Answer

N-dealkylation

Question 9

A drug has 40% absorption and a hepatic extraction ratio of 0.6. What is the bioavailability of the drug?

Accepted Answer

16%

Answer

20%

Answer

24%

Answer

28%

Question 10

Which of the following is false regarding spare receptors?

Accepted Answer

They are needed for binding a drug to achieve the maximum effect.

Answer

They respond to agonists only.

Answer

They do not alter maximal efficacy.

Answer

They can be detected by finding that EC50 < Kd for the agonist.

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?